The anti-PD1 drug nivolumab has been the first ICI drug to obtain approval by the FDA and European Commission for the treatment of RCC, and showed a significant OS benefit in patients with RCC that progressed following antiangiogenic therapy compared with everolimus (mTOR inhibitor) (26). This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.